Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | MYC | P01106 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11881146 | 0.85 | KDM4E (0.79) | KDM4EMYCCSNK2A1KMT2AMEN1 | |
| SCHEMBL25360449 | 0.84 | KDM4E (0.46) | KDM4EMYCCA1CA2CA3 | |
| SCHEMBL31481672 | 0.84 | KDM4E (0.46) | KDM4EMYCCA1CA2CA3 | |
| SCHEMBL2379171 | 0.84 | KDM4E (0.46) | KDM4EMYCMAPTGAANPC1 | |
| SCHEMBL19249161 | 0.80 | KDM4E (0.41) | KDM4EMYCMAPTGAANPC1 | |
| SCHEMBL3531504 | 0.79 | KDM4E (0.47) | KDM4EMYCGLAMAPTHSD17B10 | |
| SCHEMBL31392512 | 0.79 | KDM4E (0.42) | KDM4EMYCKMT2AMEN1MAPT | |
| SCHEMBL25170294 | 0.79 | KDM4E (0.42) | KDM4EMYCMAPTNPC1MAPK1 | |
| SCHEMBL27993371 | 0.79 | KDM4E (0.43) | KDM4EMYCKMT2AMEN1TDP1 | |
| SCHEMBL108376 | 0.79 | KDM4E (1.00) | KDM4EMYCCSNK2A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055367-A | 5-Oxo-4, 5-dihydroimidazo [1,5-a ] quinazoline compounds as PI3K [ alpha ] inhibitors | 皮卡维森治疗学股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260130925-A1 | METHODS FOR TREATING CANCER | GENESIS MOLECULAR AI INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4731626-A1 | PI3K INHIBITORS AND USE THEREOF | Regor Pharmaceuticals, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260015341-A1 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | HINOVA PHARMACEUTICALS INC (CN) | 2026-01-15 | — | — | US | disclosed |
| EP-4658657-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | Mirati Therapeutics, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250346603-A1 | TRICYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | PIKAVATION THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4646271-A1 | SUBSTITUTED SPIROCYCLIC-PYRROLOQUINAZOLINONES AND SPIROCYCLIC-PIPERIDINOQUINAZOLINONES | Mirati Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250270213-A1 | PI3Ka INHIBITORS | PIKAVATION THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| US-20250263394-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | INVENTISBIO LLC | 2025-08-21 | — | — | US | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-6005010-A | CARDIOVASCULAR DISORDERS, ANTIARRHYTHMIA AGENTS AND ANTIISCHEMIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-12-21 | — | — | US | disclosed |
| US-5945382-A | AND A METHOD OF THEIR PREPARATION BY CHLORINATION OF AN INTERMEDIATE ARYLPYRAZOLE; PROTECTION AGAINST FUNGAL DISEASES IN TOMATO, RICE, AND WHEAT PLANTS | RHONE-POULENC AGROCHIMIE (FR) | 1999-08-31 | — | — | US | disclosed |
| WO-1998047874-A1 | CRF ANTAGONISTIC QUINO- AND QUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-10-29 | — | — | WO | disclosed |
| US-5807854-A | THERAPY FOR FUNGI INFECTIONS IN PLANTS, ANIMALS | J. URIAH & CIA. S.A. (ES) | 1998-09-15 | — | — | US | disclosed |
| CN-1174833-A | Phenyl substituted alkenocarboxylic guanidine, preparation method, application as medicine or diagnostic agent adn medicine containing it | HOECHST AG (DE) | 1998-03-04 | — | — | CN | disclosed |
| EP-0825178-A1 | Phenyl-substituted alkenoylguanidides, process for their preparation, their use as drugs or in diagnostic agents and drugs containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-02-25 | — | — | EP | disclosed |
| EP-0783501-A1 | NEW PYRIMIDONE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | J. URIACH & CIA. S.A. (ES) | 1997-07-16 | — | — | EP | disclosed |
| EP-0774458-A1 | Substituted benzodicarboxylic acid diguanidines, process for their preparation, and their use as medicament or diagnostic agent | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-21 | — | — | EP | disclosed |
| WO-1997005130-A1 | NEW PYRIMIDONE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | J. URIACH & CIA. S.A. (ES) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263394-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | PIK3CD, PIK3CA, PIK3C2B | KDM4E 1844/4885MYC 486/4885CSNK2A1 349/4885 |
| US-20250346603-A1 | TRICYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | KDM4E 3686/4885MYC 453/4885CSNK2A1 650/4885 |
| US-20260015341-A1 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | PIK3CA, PIK3R4, PIK3R1 | KDM4E 1342/4885MYC 351/4885CSNK2A1 772/4885 |
| US-20250270213-A1 | PI3Ka INHIBITORS | PIK3CA, PIK3C2A, PIK3R5 | KDM4E 2515/4885MYC 312/4885CSNK2A1 491/4885 |
| US-20260130925-A1 | METHODS FOR TREATING CANCER | PIK3R1, PIK3R5, PIK3R2 | KDM4E 3903/4885MYC 605/4885CSNK2A1 99/4885 |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, F2R, PF4 | KDM4E 3061/4885MYC 4720/4885CSNK2A1 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.